Phase 3 Readout

LYEL: Phase 3 Topline: A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting C

Name: Phase 3 Topline: A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting C
Start: 2032-01-01
End: 2032-01-01

January 1, 2032 · rondecabtagene. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2032
Company: Lyell Immunopharma, Inc. (LYEL)
Drug: rondecabtagene

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting C

January 1, 2032

LYEL overview →

Company: Lyell Immunopharma, Inc. (LYEL)
Drug: rondecabtagene
Indication: Diffuse Large B Cell Lymphoma (DLBCL); Non-Hodgkin Lymphoma; Large B-cell Lymphoma